Browsing by Subject "Survival rate"
Now showing items 1-20 of 52
-
Article
Advanced stage clear-cell epithelial ovarian cancer: The Hellenic cooperative oncology group experience
(2006)Purpose.: Ovarian clear-cell carcinomas (OCCC) are known to be possibly resistant to platinum-based chemotherapy and to have a poorer prognosis with respect to other subtypes of epithelial ovarian cancer (EOC). This study ...
-
Article
Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature
(2005)Background: Brain metastases from epithelial ovarian cancer (EOC) are rare. A retrospective study of all patients diagnosed with brain metastases from EOC over the last 20 years, according to the Hellenic Cooperative ...
-
Article
Cancer of unknown primary during pregnancy: An exceptionally rare coexistence
(2015)Background: Cancer in pregnancy is a rare disease with breast cancer, cervical cancer, melanoma and Hodgkin's disease to be the most commonly diagnosed malignancies during gestation. Cancer of unknown primary (CUP) is a ...
-
Article
Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: A hellenic co-operative oncology group study
(1996)We compared, in a multicentric randomised prospective study, the efficacy and toxicity of carboplatin 400 mg/m2 as a single agent (CB) to a combination of carboplatin 300 mg/m2, epirubicin 50 mg/m2 and cyclophosphamide 500 ...
-
Article
Cavitating squamous cell lung carcinoma-distinct entity or not? Analysis of radiologic, histologic, and clinical features
(2004)Introduction: Patients with cavitating squamous lung carcinoma (cSLC) are believed to harbor aggressive, chemoresistant disease with distinct features and fare poorly. We retrospectively analyzed radiologic, histologic, ...
-
Article
Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients
(1996)A total of 209 postsurgical breast cancer patients were prospectively monitored with simultaneous serum level estimations of CA 15-3, mucin-like carcinoma-associated antigen (MCA), tumor polypeptide antigen (TPA), and ...
-
Article
Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors
(2006)Metallothioneins (MTs) are a family of cystein-rich metal-binding proteins, which are expressed in normal cells during fetal and postnatal life but also in a variety of human neoplasms. MT expression in human tumors has ...
-
Article
Combination chemotherapy with paclitaxel and gemcitabine followed by concurrent chemoradiotherapy in non-operable localized non-small cell lung cancer. A Hellenic Cooperative Oncology Group (HeCOG) phase II study
(2007)Concurrent chemoradiotherapy has become a standard therapy for locoregionally advanced inoperable non-small cell lung cancer (NSCLC). The purpose of this phase II trial was to evaluate the efficacy and toxicity of concurrent ...
-
Article
Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: A phase III randomized study. Preliminary results
(2000)Gemcitabine plus paclitaxel and paclitaxel plus carboplatin are active and well tolerated in patients with advanced non-small cell lung cancer, showing similar rates of response and survival. The Hellenic Cooperative ...
-
Article
Cyclophosphamide, mitoxantrone, fluorouracil versus conventional CMF as adjuvant treatment in node-positive breast cancer patients
(1996)362 evaluable node-positive patients with stage II breast cancer were randomized, receiving either 6 cycles of conventional CMF or 6 cycles of the combination of cyclophosphamide (500 mg/m2), mitoxantrone (Novantrone 10 ...
-
Article
The diagnosis and management of gastric cancer: Expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010
(2011)Well-recognized experts in the field of gastric cancer discussed during the 12th European Society Medical Oncology (ESMO)/World Congress Gastrointestinal Cancer (WCGIC) in Barcelona many important and controversial topics ...
-
Article
Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: A hellenic cooperative oncology group phase II study
(2000)A phase II study was conducted to evaluate the activity and toxicity profile of the combination of docetaxel and gemcitabine in anthracycline- resistant advanced breast cancer (ABC). Thirty-nine eligible patients with a ...
-
Article
Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: First report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial
(2014)Background: Dose-dense sequential chemotherapy including anthracyclines and taxanes has been established in the adjuvant setting of high-risk operable breast cancer. However, the preferable taxane and optimal schedule of ...
-
Article
The effect of homocysteine on the clinical outcomes of ventilated patients with severe sepsis
(2010)Background. There is considerable evidence that elevated plasma homocysteine levels are associated with a prothrombotic milieu, whereas activation of the coagulation cascade is an important component of the pathogenesis ...
-
Article
Elderly patients with squamous lung carcinoma: Faring better or worse?
(2006)Introduction: Nonsmall cell lung cancer is increasingly diagnosed at an advanced age and squamous cell carcinoma is the commonest histological type encountered in older patients. The clinical course, management, and outcome ...
-
Article
Evaluation of six tumor markers in patients with carcinoma of unknown primary
(1994)We have retrospectively evaluated six serum tumor markers in 85 patients with carcinoma of unknown primary. The serum levels of carcinoembryonic antigen (CEA), CA 19‐9, CA 15‐3, CA 125, β‐chorionic gonadotropin (β‐HCG) and ...
-
Article
Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: Pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials
(2013)Background: The HER2 gene has been established as a valid biological marker for the treatment of breast cancer patients with trastuzumab and probably other agents, such as paclitaxel and anthracyclines. The TOP2A gene has ...
-
Article
Extraskeletal Ewing's sarcoma. Presentation of two cases and review of the literature
(1991)We present here two cases extraskeletal Ewing's sarcoma, the first in a 50-year-old female and the second in a 25-year-old male. We discuss the clinical picture, histopathology and therapeutic management. The literature ...
-
Article
Forty years experience of treating cancer of unknown primary
(2007)Cancer of unknown primary site (CUP) is not a rare tumour. It accounts as the seventh to eighth most frequently diagnosed cancer in a general medical oncology service. Since CUP is not a homogeneous disease and it consists ...
-
Article
Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: A quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial
(2009)Background Estrogen receptor (ER) and progesterone receptor (PgR) protein expression carry weak prognostic and moderate predictive utility for the outcome of early breast cancer patients on adjuvant chemohormonotherapy. ...